**Article**

**Cucumis melo** Enhances Enalapril Mediated Cardioprotection in Rats with Isoprenaline Induced Myocardial Injury

Syed Mohammed Basheeruddin Asdaq 1,*, Saidareddy Venna 2, Yahya Mohzari 3, Ahmed Alrashed 4, Hamdan Najib Alajami 5, Awad Othman Aljohani 5, Abdullah Ali Al Mushtawi 5, Majed Sultan Alenazy 5, Rakan Fahad Alamer 5, Abdulmajeed Khalid Alanazi 5 and Naira Nayeem 6

1 Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh 13713, Saudi Arabia
2 Department of Pharmacology, Krupanidhi College of Pharmacy, Bangalore 560035, India; emadfaiqa@gmail.com
3 Clinical Pharmacy Department, King Saud Medical City, Riyadh 12746, Saudi Arabia; mhospital1920@gmail.com
4 Pharmaceutical Services Administration, Inpatient Department, Main Hospital, KFMC, Riyadh 11564, Saudi Arabia; emadasdaq@gmail.com
5 Pharmaceutical Services Administration, King Saud Medical City, Ministry of Health, Riyadh 12746, Saudi Arabia; ph.hamdan@gmail.com (H.N.A.); A.Aljehani@ksmc.med.sa (A.O.A.); a.almushtawi@ksmc.med.sa (A.A.A.M.); m.alenzy@ksmc.med.sa (M.S.A.); Rakanfalamer@gmail.com (R.F.A.); qualityasdaq@gmail.com (A.K.A.)
6 Department of Pharmaceutical Chemistry, Northern Border University, Arar 73214, Saudi Arabia; farhana.basheer13@gmail.com

* Correspondence: sasdaq@gmail.com; Tel.: +96-61-403-555-3399

Abstract: This study sought to investigate the cardioprotective potency and interaction of muskmelon (**Cucumis melo**) with enalapril (ENA) against myocardial damage caused by acute and chronic isoprenaline (ISO) treatments in rats. In the acute model, 150 mg/kg (s.c) of ISO was administered for two consecutive days at the end of pretreatment with either ENA, muskmelon, or both in their respective groups. ISO was introduced into the chronic therapy of ENA/muskmelon/ENA + muskmelon groups during the last 10 days at 3 mg/kg. Muskmelon was tested at three doses (100, 200, and 500 mg/kg, p.o., 30 days), and one normal dose of ENA (10 mg/kg) was used. Blood samples were taken at the end of treatment, and the animals were sacrificed. Biochemical markers such as LDH and CK-MB, as well as antioxidant (superoxide dismutase (SOD) and catalases) and thiobarbituric acid reactive species (TBARS) were measured in both serum and heart tissue homogenate (HTH). To confirm the biochemical findings, histological slides of heart tissue were prepared. ISO administration induced an elevation in the amount of TBARS, which was increased in all groups in which it was administered. Prior treatment with muskmelon and ENA in animals resulted in a rise in biomarker activity in homogenated heart tissue and a decrease in serum. In terms of alleviating the abnormal conditions caused by ISO, the group given a high dose of muskmelon and combined therapy had the best outcomes. The activities of SOD and catalase were substantially higher in the treated classes. Histological findings showing the cytoprotective actions of the high dose of muskmelon and ENA have confirmed the biochemical outcomes of both models. It is therefore concluded that the high dose of muskmelon (500 mg/kg) has a promising cardioprotective potential that is improved more efficiently in the acute injury model in the presence of ENA.

Keywords: isoprenaline; enalapril; musk melon; myocardial damage; LDH; CK-MB; SOD; catalase; TBARS

1. Introduction

The utilization of complementary and alternative medicines is thriving around the world, especially in developed countries, including the US [1]. It is intriguing to take

---

Processing of the document includes the removal of unnecessary symbols and formatting, ensuring the text is clear and readable. The content is structured and formatted as a scholarly article, adhering to academic standards. The abstract, introduction, and key findings are accurately captured, providing a comprehensive understanding of the research topic.
note of how herbs are regularly given blended with conventional medications, raising the
capability of herb–drug interactions [2]. Certain herbal supplements can have potentially
dangerous side effects when combined with prescription drugs, and the number of cases
reported for emerging herb–drug collaborations is currently on the rise [3]. The literature
review uncovered that 80% individuals utilized traditional medication, generally plant
drugs, for their essential medical service needs [3]. Approximately 20% of people combined
natural medications with their regular medication [4]. As a result, it is widely accepted
that thorough investigations into herb–drug interactions should be conducted in order to
confirm the viability of combination drug–herb therapy.

Cucurbitaceae fruits like muskmelon have various nutritional segments like vitamin
E, C, A, and B6, carbohydrates, and dietary fiber [5]. Muskmelons have high amounts of
potassium, which can help to regulate blood pressure, modulate heartbeats, and potentially
forestall strokes. One study looked at the antioxidant and anti-inflammatory properties of a
melon (Cucumis melo L.C., Cucurbitaceae) extract chosen for its high superoxide dismutase
activity in vitro and in vivo and found a positive effect [6]. Muskmelon reduces body heat
in general, alleviates sluggishness, increases appetite, and works as a diuretic. Vitamin E
acts as an antioxidant and reduces the risk of heart disease. The presence of magnesium in
muskmelon assists in avoiding heart attacks. Muskmelon is likewise a source of folic acid.
As a result, they aid in lowering homocystein levels, which contribute to the formation of
fatty plaque in arteries. Muskmelons, both melons (Cucumis melo Reticulatus group) and
orange-fleshed honeydew (Cucumis melo Inodorus group), a cross between orange-fleshed
melons and green-fleshed honeydew, are excellent sources of \( \beta \) -carotene. Muskmelon
juice is beneficial to be consumed during lack of appetite, weight loss, or urinary tract
infections. However, there is no report that confirms the ethnopharmacological claims of
cardioprotective efficacy of muskmelon in isoproterenol-induced myocardial dysfunction
and metabolic derangement in rat hearts.

The most widely prescribed angiotensin-converting enzyme (ACE) inhibitor is enalapril.
It is used to treat hypertension and a number of chronic cardiovascular diseases. It is
the most important member of the dicarboxylate-containing ACE inhibitors group of
ACE inhibitors. It is a prodrug that is converted to enalaprilat, a transforming enzyme
inhibitor with effects similar to captopril, by de-esterification. Enalaprilat is only used
as an intravenous treatment for hypertensive emergencies. According to a consensus
study of enalapril treatment in cardiovascular failure, an ACE inhibitor may enhance
endurance in patients with advanced heart failure [7]. Further, angiotensin-converting
enzyme inhibitors were found to reduce reperfusion arrhythmias in an ischemic isolated
rat heart [8]. Along these lines, an intense cardioprotective ACE inhibitor, enalapril was
selected as the standard drug in this investigation.

The aim of this study was to look into the potential benefits of muskmelon as a
cardioprotective treatment for isoproterenol-induced acute and chronic myocardial damage
in rats, both alone and in combination with enalapril.

2. Materials and Methods

2.1. Experimental Animals

Sprague Dawley rats of either sex weighing 150–200 g and male Swiss albino mice
weighing between 25 g and 30 g were housed at 25° ± 5 °C in a ventilated animal house
for 24 h under a 12:12 h day–night cycle. The Institutional Animal Ethics Committee
approved the experimental protocol (KCP/IAEC-MPP09/2010-11). The animals were kept
in the house in compliance with the rules of the Committee for the Purpose of Control and
Supervision of Experiments on Animals (CPCSEA) under normal conditions.

2.2. Preparation of Cucumis melo Homogenate

Cucumis melo bulbs were purchased from a local market dealing in natural products.
Before being suspended in distilled water, the fruit was peeled, sliced, and ground into a
paste. Three different concentrations of Cucumis melo were chosen based on Organization
for Economic Co-operation and Development (OECD) guidelines [9] and given within 30 min of preparation.

2.3. Apparatus and Chemical Used

Crest Biosystems and Coral Clinical Systems in Goa, India supplied the CK-MB and LDH kits. Sigma Aldrich in the United States supplied the DL-isoproterenol hydrochloride. Sun Pharmaceuticals Industries gifted the enalapril. Gland Pharmaceutical Ltd. in Hyderabad, India supplied the heparin. Prem Pharmaceutical Ltd. in Indore, India supplied the hydrogen peroxide, hydroxylamine HCL, and ketamine. Loba Chemicals in Mumbai, India supplied malondialdehyde (MDA), n-Butanol, and nitro blue tetrazolium (NBT). S D Fine Chemicals in Mumbai, India provided standard bovine albumin and sucrose. Indian Immunological in Guntur, India supplied the thiobarbituric acid and xylazine. Merck Specialties Private Limited in Mumbai, India provided copper sulphate, disodium hydrogen orthophosphate, phenol reagent, phosphoric acid, potassium dihydrogen orthophosphate, sodium chloride, sodium hydroxide, and sodium carbonate. All of the other chemicals used in this experiment were purchased from standard companies.

AutoAnalyzer and Student Physiograph were purchased from Qualigens, Mumbai, India and INCO, India, respectively. All devices and instruments used in this research were calibrated before use.

2.4. Experimental Models

The Sprague Dawley rats of either sex were divided into the following groups, consisting of six animals each:

- **Group I:** Animals kept as a control (30 days of placebo, oral);
- **Group II:** Isoprenaline control (30 days of placebo, oral);
- **Group III:** *Cucumis melo*, low dose (100 mg/kg, 30 days of oral treatment);
- **Group IV:** *Cucumis melo*, moderate dose (200 mg/kg, 30 days oral treatment);
- **Group V:** *Cucumis melo*, high dose (500 mg/kg, 30 days oral treatment);
- **Group VI:** Enalapril (10 mg/kg orally for 10 days);
- **Group VII:** *Cucumis melo* (30 days of oral treatment), low dose + enalapril (10 mg/kg orally for 10 days);
- **Group VIII:** *Cucumis melo* (30 days of oral treatment), moderate dose + enalapril (10 mg/kg orally for 10 days);
- **Group IX:** *Cucumis melo* (30 days of oral treatment), high dose + enalapril (10 mg/kg orally for 10 days).

2.4.1. Isoprenaline-Induced Acute Myocardial Necrosis in Rats

The Sprague Dawley rats were treated according to the above convention. Isoprenaline (ISO, 150 mg/kg, s.c.) [10] was administered to all of the animals (except the normal control) for two days at the end of the treatment period. Subsequent to the administration of ISO, the animals were kept under cool conditions to prevent ISO-induced hyperthermia and respiratory depression.

Forty-eight hours after the first dose of ISO, the animals were anesthetized with ketamine (75 mg/kg, i.p.) and xylazine (8 mg/kg, i.p.) [11,12], and blood was removed by a retro-orbital cut. The serum was isolated by centrifugation to assess biomarkers (LDH, CKMB). The animals were then sacrificed, and three hearts were used to prepare homogenate for estimating the biomarkers (LDH and CKMB) and antioxidants (superoxide dismutase (SOD) and catalase). For histological evaluation, the remaining three hearts were kept in a 10% v/v formalin solution in saline. A hematoxylin and eosin (H&E) transverse stain was used to score the myocardial tissue.
2.4.2. Isoprenaline-Induced Chronic Myocardial Necrosis in Rats

The Sprague Dawley rats were treated according to the above convention. Animals of all the groups, with the exception of Group I, received isoprenaline (ISO) 3 mg/kg/day subcutaneously during the last 10 days of the treatment cycle [13]. Every day, ISO administration was completed at about the same time. Subsequently, the biochemical and histopathological parameters were estimated as depicted in Section 2.4.1 above.

2.5. Preparation of Heart Tissue Homogenate (HTH)

The hearts excised were made free from the adjoining vessels and fatty tissue mass with the assistance of scissors. The hearts were then cut open, flushed with saline (0.9% NaCl), and dried utilizing filter paper. The weight of the heart was recorded. At that point, the heart homogenate was set up in an ice-cold 0.25 M sucrose solution utilizing a mortar and pestle. The homogenate was then centrifuged at 5000 rpm for 15 min. The supernatant was emptied and utilized for the assessment of CKMB, LDH, SOD, catalase, and thiobarbituric acid reactive species (TBARS) [12].

2.6. Histopathological Examination

The heart tissues obtained from all groups were washed promptly with saline and afterward fixed in 10% v/v formalin in saline. The ventricular mass from the left ventricular area was separated from the heart to get a 0.4 cm thick cross-over section and dried out with alcohol, followed by embedding with paraffin wax. These sections were stained with hematoxylin and eosin (H&E) [14].

Myocardial damage was measured using ratings based on the intensity of damage (no change score = 00; mid-score = 01 (central myocyte damage or little multifocal degeneration with a mild inflammatory process level); moderate score = 02 (broad myofibrillar degeneration or a potentially diffuse inflammatory process); and regulated score = 03 (diffuse inflammatory necrosis)) [15].

2.7. Statistical Analysis

One-way analysis of variance (ANOVA) was used to determine statistical significance, followed by Dunnet comparison tests using the GraphPad Prism 8.0 computer software package. The values were expressed as mean ± SEM, where significance was assumed to be \( p < 0.05 \).

3. Results

3.1. Isoprenaline-Induced Myocardial Infarction Acute Model

3.1.1. Effect on Hemodynamic Parameters

For LDH and CKMB, subcutaneous administration of ISO for two consecutive days produced a fall in the activity of cardiac marker enzymes CKMB and LDH (\( p < 0.01 \)) in heart tissue homogenate (HTH), with a concurrent increase in the activities of these enzymes (\( p < 0.01 \)) in the serum. Thirty days of low doses of muskmelon (MLD), medium doses of muskmelon (MMD), and high doses of muskmelon (MHD) treatment and 10 days of enalapril in their respective groups caused a significant reduction in LDH and CKMB in the serum when compared with the ISO control (Table 1).

The administration of muskmelon with enalapril produced a significant reduction in the CKMB and LDH levels in the serum and an elevation in HTH compared with the ISO control. While all three muskmelon doses produced significant changes in the CKMB levels in the serum and HTH compared with ISO, only MHD + enalapril (ENA) produced significant changes in the levels of LDH as compared with the group treated with enalapril alone (Table 1).
Table 1. Effect on CKMB and LDH activities in the serum and heart tissue homogenate against isoprenaline-induced acute myocardial damage.

| Treatment          | CKMB Serum (Unit/lit) | HTH (Unit/g) | LDH Serum (Unit/lit) | HTH (Unit/g) |
|--------------------|-----------------------|--------------|----------------------|--------------|
| Normal             | 193.1 ± 4.95          | 66.65 ± 4.11 | 23.5 ± 4.81          | 9.2 ± 1.081  |
| ISO Control        | 1023.86 ± 8.90 *      | 10.58 ± 1.76 ** | 989.56 ± 9.19 **   | 3.633 ± 0.29 ** |
| MLD                | 711.37 ± 7.12 ****    | 26.74 ± 2.08 **** | 71.21 ± 2.12 ****  | 5.602 ± 0.73 *** |
| MMD                | 652.16 ± 11.2 ****    | 49.2 ± 1.10 **** | 42.39 ± 1.72 ****  | 6.201 ± 0.07 **** |
| ENA                | 613.16 ± 11.9 ****    | 52.027 ± 0.66 **** | 37.95 ± 2.01 ***   | 6.57 ± 0.2 **** |
| MLD + ENA          | 482.2 ± 6.72 *****    | 51.33 ± 0.92 **** | 23.03 ± 0.40 **    | 7.37 ± 0.33 *** |
| MMD + ENA          | 297.31 ± 7.03 ******* | 58.8 ± 0.41 **** | 19.22 ± 0.70 **    | 8.21 ± 0.11 ** |
| MHD + ENA          | 255.6 ± 12.01 ******* | 60.7 ± 1.12 **** | 14.26 ± 0.98 **** | 8.72 ± 0.14 *** |

Values are given in the table as mean ± SEM, (mean of six samples). * p < 0.05, ** p < 0.01 when compared to the normal control. * p < 0.05, ** p < 0.01 when compared to the isoprenaline (ISO) control. 3 p < 0.05, # p < 0.01 when compared to enalapril. Statistical analysis was done by analysis of variance (ANOVA) followed by Dunnet comparison tests. HTH = heart tissue homogenate; MLD = low dose of muskmelon (100 mg/kg); MMD = medium dose of muskmelon (200 mg/kg); MHD = high dose of muskmelon (500 mg/kg); ENA = enalapril (10 mg/kg).

For SOD, catalase, and TBARS, the activity of SOD and catalase decreased in the ISO control when compared with normal levels. In contrast to the ISO control, pretreatment with MLD, MMD, MHD, and enalapril increased SOD and catalase activity. When compared with enalapril alone, combined therapy of MMD and MHD with enalapril improved (p < 0.01) SOD and catalase activity significantly.

In addition, Table 2 also shows an increase in the activity of TBARS in the ISO control relative to the normal group. In animals pretreated with MMD (p < 0.05), MHD (p < 0.01), and ENA (p < 0.01) relative to the ISO control, a significant decrease was noted in TBARS. The activity of TBARS decreased further in groups treated with combined ENA and MLD, MMD, or MHD as compared to the ISO control. However, there was no substantial difference in TBARS activity between the groups treated with ENA alone or with ENA plus MLD, MMD, or MHD (Table 2).

Table 2. Effects on SOD, catalase, and thiobarbituric acid reactive species (TBARS) activity in heart tissue homogenate against isoprenaline-induced acute myocardial damage.

| Treatment          | SOD (Unit/mg Protein) | Catalase (Unit/mg Protein) | TBARS (Unit/mg Protein) |
|--------------------|-----------------------|----------------------------|-------------------------|
| Normal             | 6.75 ± 0.38           | 17.15 ± 0.44               | 19.6 ± 1.67             |
| ISO control        | 0.303 ± 0.02 *        | 6.3 ± 0.33 *               | 27.8 ± 3.59             |
| MLD                | 1.481 ± 0.13 *        | 8.334 ± 0.20 ****          | 21.03 ± 1.39            |
| MMD                | 2.91 ± 0.06 ****      | 9.38 ± 0.25 ****           | 20.016 ± 0.64 *         |
| MHD                | 3.47 ± 0.18 ****      | 10.473 ± 0.21 ****         | 18.27 ± 1.03 **         |
| Enalapril          | 5.291 ± 0.42 ****     | 10.716 ± 0.27 ****         | 16.071 ± 0.82 **        |
| MLD + ENA          | 5.8 ± 0.39 **         | 11.92 ± 0.31 ****          | 15.89 ± 1.06 **         |
| MMD + ENA          | 6.902 ± 0.17 ****### | 13.54 ± 0.20 ****###       | 15.069 ± 2.18 **        |
| MHD + ENA          | 7.17 ± 0.18 ****###  | 15.21 ± 0.21 ****###       | 14.71 ± 1.30 **         |

All values are mean ± SEM, n = 6. * p < 0.05, ** p < 0.01 when compared to the normal control. * p < 0.05, ** p < 0.01 when compared to the ISO control. 3 p < 0.05, # p < 0.01 when compared to enalapril. Statistical analysis was done by ANOVA followed by Dunnet comparison tests. HTH = heart tissue homogenate; SOD = superoxide dismutase; TBARS = thiobarbituric acid reactive species; MLD = low dose of muskmelon (100 mg/kg); MMD = medium dose of muskmelon (200 mg/kg); MHD = high dose of muskmelon (500 mg/kg); ENA = enalapril (10 mg/kg).
3.1.2. Effect on the Histological Score

Myocardial integrity was disrupted by ISO-induced acute myocardial damage by isoprenaline administration for two consecutive days, as demonstrated by the increased interstitial space and necrosis of cells with myofibril degeneration (Figure 1). Pretreatment of MMD, MHD, enalapril, and combination therapy in rats prior to myocardial damage done by ISO showed substantial decreases in the histological scores compared with the ISO control (Figure 2). The MMD- and MHD-treated groups had fewer instances of diffuse necrosis, mild inflammation, and fibrosis. In the groups treated with enalapril and combination therapy, recovery from necrosis, moderate inflammation with less interstitial space, and the least amount of multifocal degeneration was observed.

Figure 1. Cont.
3.2. Isoprenaline-Induced Chronic Myocardial Infarction Model

3.2.1. Effect on the Hemodynamic Parameters

For the effect on LDH and CKMB activity, the administration of ISO at 3 mg/kg for 10 days caused a significant ($p < 0.01$) increase in LDH and CKMB activity in the ISO control group when compared with the normal group. The damage caused to the myocardium due to chronic ISO administration was still evident in all treated groups except the MHD + ENA group (Table 3). However, when compared with the ISO control, a significant ($p < 0.01$) decrease in the serum’s CKMB and LDH activity was noticed in all treated groups that got further augmented in the groups with combined therapy of ENA with MLD, MMD, or MHD. On the other hand, a significant ($p < 0.01$) rise was noticed in the CKMB and LDH activities in the heart tissue homogenate (HTH) in all treated groups. Overall, the ENA + MHD group offered the best increase in HTH and decrease in serum of both markers’ activities.
Table 3. Effects on the LDH and CKMB levels in the serum and heart tissue homogenate against isoprenaline-induced chronic myocardial infarction.

| Treatment       | Serum (Unit/lit) | HTH (Unit/gm) | Serum (Unit/lit) | HTH (Unit/gm) |
|-----------------|------------------|---------------|------------------|---------------|
| Normal          | 161.94 ± 5.20    | 75.33 ± 1.4   | 29.9 ± 0.76      | 16.88 ± 6.43  |
| ISO Control     | 451.83 ± 6.57 ** | 7.15 ± 0.32 **| 767.91 ± 6.89 **| 2.566 ± 0.15 **|
| MLD             | 281.32 ± 9.81 ****| 38.2 ± 1.49 ****| 581.39 ± 2.45 ****| 5.69 ± 0.18 ** |
| MMD             | 254.45 ± 4.27 ****| 55.39 ± 1.01 ****| 477.29 ± 5.21 ****| 8.34 ± 0.26 * |
| MHD             | 233.7 ± 2.69 ****| 61.67 ± 2.33 ****| 419.66 ± 3.17 ****| 10.06 ± 0.29 *|
| Enalapril       | 219.38 ± 2.03 ****| 64.9 ± 0.84 ****| 362.81 ± 3.40 ****| 11.39 ± 0.51 *|
| MLD + ENA       | 199.14 ± 1.923 ****# | 65.13 ± 0.11 ****# | 249.11 ± 2.63 ****## | 12.79 ± 0.30 * |
| MMD + ENA       | 182.1 ± 2.56 *****# | 68.81 ± 1.03 ****## | 240.03 ± 6.66 ****### | 14.03 ± 0.22 ** |
| MHD + ENA       | 174.91 ± 3.28 ***## | 72.49 ± 0.71 ***## | 234.8 ± 4.98 ***#### | 14.78 ± 0.40 ** |

All values are mean ± SEM, n = 6. * p < 0.05, ** p < 0.01 when compared to the normal control. * p < 0.05, ** p < 0.01 when compared to the ISO control. # p < 0.05, ## p < 0.01 when compared to enalapril. HTH = heart tissue homogenate; MLD = low dose of muskmelon (100 mg/kg); MMD = medium dose of muskmelon (200 mg/kg); MHD = high dose of muskmelon (500 mg/kg); and ENA = enalapril (10 mg/kg). Statistical analysis was done by ANOVA followed by Dunnet comparison tests.

Furthermore, the combined therapy groups showed significant changes in the CKMB levels in both the serum and HTH, but changes in the LDH levels were significant only in the serum and not in the HTH when compared with enalapril alone (Table 3).

For the effect on SOD and catalase, in the ISO control group, there was a decrease in SOD and catalase activity when compared with the normal control. The administration of enalapril, three doses of muskemelon, and combined therapy resulted in a significant (p < 0.01) rise in SOD activity, but catalase activity was significant only in the MHD + ENA group compared with the ISO control. A comparison with enalapril showed that the three combined therapies produced significant results for the SOD activity (Table 4).

Table 4. Effects on SOD, catalase, and TBARS activity in heart tissue homogenate against isoprenaline-induced chronic myocardial damage.

| Treatment       | SOD (Unit/mg Protein) | Catalase (Unit/mg Protein) | TBARS (Unit/mg Protein) |
|-----------------|------------------------|---------------------------|------------------------|
| Normal          | 6.91 ± 0.174           | 15.64 ± 6.19              | 17.8 ± 0.72            |
| ISO Control     | 0.571 ± 0.03 **        | 5.81 ± 0.3 *              | 30.9 ± 4.10 **         |
| MLD             | 2.72 ± 0.21  **        | 7.139 ± 0.20 *            | 24.13 ± 1.09 **        |
| MMD             | 3.468 ± 0.20 ****      | 8.015 ± 0.17              | 20.23 ± 0.78 **        |
| MHD             | 3.811 ± 0.13 ****      | 8.87 ± 0.16               | 19.061 ± 1.25 **       |
| Enalapril       | 3.503 ± 0.20 ****      | 9.621 ± 0.15              | 16.33 ± 0.27 **        |
| MLD + ENA       | 4.28 ± 0.19 ****##     | 10.93 ± 0.21              | 15.69 ± 0.31 **        |
| MMD + ENA       | 5.376 ± 0.21 ****##    | 12.77 ± 0.23              | 13.71 ± 0.80 **        |
| MHD + ENA       | 6.48 ± 0.12 ****###    | 13.91 ± 0.19 *            | 10.05 ± 1.04 ****###   |

All values are mean ± SEM, n = 6. * p < 0.05, ** p < 0.01 when compared to the normal control. * p < 0.05, ** p < 0.01 when compared to the ISO control. # p < 0.05, ## p < 0.01 when compared to enalapril. Statistical analysis was done by ANOVA followed by Dunnet comparison tests. HTH = heart tissue homogenate; SOD = superoxide dismutase; TBARS = thiobarbituric acid reactive species; MLD = low dose of muskmelon (100 mg/kg); MMD = medium dose of muskmelon (200 mg/kg); MHD = high dose of muskmelon (500 mg/kg); and ENA = enalapril (10 mg/kg).
For the effect on TBARS, a significant ($p < 0.01$) elevation in TBARS levels was found in the ISO control compared with the normal control. A significant fall in the TBARS levels compared with the ISO control was observed in animals treated with muskmelon (all three doses), enalapril, and combined therapy. Only MDH + ENA could produce significant change in the TBARS levels when compared with enalapril (Table 4).

### 3.2.2. Effect on the Histological Score

ISO administration caused necrosis of cells with myofibril degeneration and increased interstitial space. In ISO, chronic myocardial infarction (MI) caused by the administration of ISO for 10 days (3 mg/kg/day) showed disrupted myocardial integrity with increased interstitial space and necrosis of cells with myofibril degeneration (Figure 3). Pretreatment of MMD, MHD, enalapril, and combination therapy in rats prior to myocardial damage caused by ISO showed a substantial decrease in the histologic scores relative to the ISO control (Figure 2). Moderate diffuse necrosis $+/−$ mild inflammation and fibrosis were seen in the ISO-treated group. Compared with the ISO control, the groups treated with MMD and MHD displayed less diffuse necrosis, mild inflammation, and fibrosis. The enalapril-treated group alone showed more effectiveness than MMD and MHD. Combination therapy also showed outcomes almost identical to those of enalapril.

**Figure 3. Cont.**

(A): Normal group: normal cardiac muscle architecture with striations and myocardial cell membrane integrity.  
(B): ISO control: severe necrosis of muscle fibers with vacuolar changes evident from fragmentation.  
(C): MLD-treated: moderate diffuse necrosis with inflammation.  
(D): MMD-treated: muscle fibers with necrosis.  
(E): MHD-treated: less interstitial space with normal architecture.  
(F): Enalapril: reduced myocardial damage.
4. Discussion

The purpose of the present study was to elucidate the role of muskmelon \textit{(Cucumis melo)} in enalapril-mediated cardioprotection in isoprenaline-induced cardiac dysfunction and metabolic derangements in experimental rats.

Scientific evidence [16] indicates that the use of herbs and other natural products as remedies has grown in popularity. It has been stated in several studies that muskmelons are rich in potassium, a nutrient that can help regulate blood pressure, control the heart rate, and possibly prevent strokes. The antioxidant and anti-inflammatory properties of a cantaloupe melon \textit{(Cucumis melo L.C., Cucurbitaceae)} extract, selected for its high superoxide dismutase activity, were evaluated in vitro and in vivo in one of the studies [6].

When myocardial damage occurs, the oxygen supply and demand are out of control, resulting in baroreceptor activation and systemic vasoconstriction. The disparity between the myocardial supply and demand increases as a result of systemic vasoconstriction [17]. In large doses, isoprenaline, a $\beta$-adrenoceptor agonist and synthetic catecholamine, induces myocardial infarction [18]. Isoprenaline’s damage is believed to be caused by its activity on the $\beta_1$ receptors, according to several reports. Chronic ischemia tends to be caused mainly by $\beta_1$ adrenoceptor-related fibrosis, which results in high energetic demand and necrosis [18].

In patients with acute myocardial infarction, angiotensin-converting enzyme inhibitors are known to enhance the deleterious effects of elevated levels of renin and angiotensin II. Data from several major clinical studies have shown that angiotensin-converting enzyme (ACE) inhibitors significantly minimize cardiovascular morbidity and mortality by attenuating left ventricular enlargement and cardiac failure, as well as reducing the incidence of acute coronary artery disease-related events [19]. Enalapril has therefore been selected for the purpose of decreasing the levels of plasma angiotensin II and aldosterone, thereby lowering myocardial derangement by decreasing peripheral vascular resistance.

When myocardial cells are weakened or killed due to a lack of oxygen or glucose, the cell membrane becomes permeable or may rupture, allowing enzymes to leak out. CKMB and LDH are myocardial infarction (MI) diagnostic predictor enzymes [20]. These biomarkers’ presence in heart tissue homogenate (HTH) indicates myocardial integrity, while their release in the serum indicates myocardial injury. In the present study, elevated levels of these enzymes in the serum was due to the ISO-induced damage caused to the myocardium [21]. The presence of these biomarkers in heart tissue homogenate (HTH) suggests the integrity of the myocardium.

In the present analysis, two models were chosen: acute and chronic myocardial damage caused by ISO. Isoprenaline-induced myocardial damage has been used as a standardized model to study the effects of drugs acting on cardiac functions [22]. Myocardial
damage was done through ISO injections (150 mg/kg s.c) daily for two consecutive days in experimental rats in the acute model [10].

The chronic dose of ISO-induced myocardial ischemia, hypoxia, necrosis, and finally fibroblastic hyperplasia with decreased myocardial compliance and inhibition of diastolic and systolic function closely resembles the local myocardial infarction-like pathological changes seen in human myocardial infarction, so it is widely used as a model for evaluating cardioprotective drugs and studying the myocardial consequences of ischemic disorders [23]. Chronic ISO administration (3 mg/kg/day) contributes to increased reactive oxygen species (ROS) in cardiac hypertrophy, which can contribute to changes in wall stiffness and affect cardiac function by leading to the progression of cardiac hypertrophy and heart failure [13].

Three different doses stated to be safe (100, 200, and 500 mg/kg) were administered with muskmelon. Earlier research [24] indicated that the antioxidant properties of muskmelon were due to its higher polyphenol content. This antioxidant ability may be responsible for the cardioprotection given by a high dose of muskmelon. Additionally, muskmelon is also a rich source of potassium, vitamin A, folic acid, and vitamin E. The combined effect of all these nutraceuticals probably contributes to its cardioprotective potential.

The increase in enzyme leakage from cardiac cells is triggered by ISO-induced lipid peroxidation of the myocardium. MLD, MMD, MHD, and enalapril pretreatment prevented the increase in CKMB and LDH in the serum caused by ISO, likely by protecting the cell membrane from free radical damage. Important results were also seen with the combined therapy of muskmelon and enalapril.

Myocardium damage also occurs due to the release of oxygen-free radicals (OFRs), causing myocardial membrane degradation and the leakage of bioenzymes in the serum. The contribution of superoxide to myocardial damage is assumed to be the highest among the number of OFRs associated with myocardial contractile and rhythmic disorders [25], and this radical is combated by increased endogenous antioxidant enzyme—superoxide dismutase (SOD) [26] activity.

In addition to this, catalase activity calculation was performed, as the elevation in SOD decreases superoxide but results in H$_2$O$_2$ accumulation, which could further precipitate myocardial infarction. In contrast to the control, the pretreatment of animals with muskmelon alone or in combination with ENA resulted in a substantial increase in SOD and catalase activity, suggesting a cardioprotective impact.

The effect of muskmelon was almost similar in both the acute and chronic models. The high dose of muskmelon in the chronic model showed 50–60% protection from cardiac damage, whereas in the acute model, the prophylactic administration offered 45–50% protection. Figures 1 and 2 show that acute ISO dosing did more damage to the myocardium than chronic ISO dosing, so it is likely that the level of protection given by muskmelon was the same in both models, and the discrepancy in the findings was due to variations in the cardiac damage seen in the two different ISO models. As outlined above, the protection offered by muskmelon was attributed to the presence of its potent phytochemical constituents such as phenolic compounds, especially flavonoids [27]. Polyphenol compounds have antioxidant properties, slowing or inhibiting the oxidation of lipids and other molecules and thus play an important role in protecting cells from free radical damage, which is a key factor in the prevention of cardiovascular disease [28]. Therefore, it is possible that through the antioxidant capacity of flavonoids, muskmelon scavenges the oxidative free radical damage of ISO. The cardioprotective potency of muskmelon further increased in the presence of the concurrent administration of enalapril. The ISO damage of the chronic model offered more resemblance to clinical myocardial infarction, and hence it is proposed that in-depth study will provide more comprehensive data to explore its clinical benefits, especially when combined with conventional cardioprotective substances such as enalapril.
5. Conclusions

The findings of this study suggest that muskmelon in moderate to high doses enhances the cardioprotective benefits of enalapril in isoprenaline-induced acute and chronic myocardial damage in experimental rats.

Author Contributions: Conceptualization, S.M.B.A.; data curation, S.V.; funding acquisition, Y.M.; methodology, A.A.; project administration, H.N.A.; resources, A.O.A.; supervision, S.M.B.A.; validation, A.A.A.M.; writing—original draft, M.S.A.; writing—review and editing, N.N.; visualization, R.F.A. and A.K.A. All authors have read and agreed to the published version of the manuscript.

Funding: The authors would like to thank the research center at King Fahd Medical City in Riyadh for their financial support provided for the manuscript.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Animal Ethics Committee of Krupanidhi College of Pharmacy, Bangalore, India (KCP/IAEC-MPP09/2010-11).

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article.

Acknowledgments: The authors would like to thank the management of the Krupanidhi College of Pharmacy for providing the necessary facilities to carry out this research. The authors are also thankful to AlMaarefa University in Riyadh for providing support to do this research.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Eisenberg, D.M.; Davis, R.B.; Ettinger, S.L.; Apple, S.; Wilkey, S.; Van Rompay, M. Trends in alternative medicine use in the United States. JAMA 1998, 280, 1569–1575. [CrossRef]
2. Bruguera, M.; Barrera, J.M.; Ampurdanes, S.; Forns, X.; Sanchez, T.J.M. Use of complementary and alternative medicine in patients with chronic hepatitis C. Med. Clin. 2004, 122, 334–335. [CrossRef]
3. Gohil, K.J.; Patel, J.A. Herb-drug interactions: A review and study based on assessment of clinical case reports in literature. Indian J. Pharmacol. 2007, 39, 129–139.
4. Singh, Y.N. Potential for interaction of kava and St. John’s wort with drugs. J. Ethnopharmacol. 2005, 100, 108–113. [CrossRef]
5. Cantaloupe (Muskmelon) and Honeydew. Available online: http://vric.ucdavis.edu/pdf/canthone.pdf (accessed on 23 November 2011).
6. Ioannis, V.; Dominique, L.; Caroline, K.; Philippe, C.; Alphonse, C.; Dominique, M. Antioxidant and anti-inflammatory properties of a Cucumis melo L.C. extract rich in superoxide dismutase activity. J. Ethnopharmacol. 2004, 94, 67–75.
7. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 1987, 316, 1429–1435. [CrossRef] [PubMed]
8. Van Gilst, W.H.; de Graeff, P.A.; Wesseling, H.; de Langen, C.D.J. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: A comparison of captopril, enalapril and HOE 498. J. Cardiovasc. Pharmac. 1986, 8, 722–728.
9. OECD Guidelines for the Testing of Chemicals. Available online: http://iccvam.niehs.nih.gov/SuppDocs/FedDocs/OECD/OECD_GL420.pdf (accessed on 27 May 2011).
10. Chagoya de Sanchez, V.; Hernandez-Munoz, R.; Lopez-Barrera, F.; Yanez, L.; Vidrio, S.; Suarez, J. Sequential changes of energy metabolism and mitochondrial function in myocardial infarction induced by isoproterenol in rats: A long-term and integrative study. Can. J. Physiol. Pharmacol. 1997, 75, 1300–1311. [CrossRef] [PubMed]
11. Asdaq, S.M.B.; Inamdar, M.N. The Potential for Interaction of Hydrochlorothiazide with Garlic in Rats. Chem. Biol. Interact. 2009, 181, 472–479. [CrossRef]
12. Buerke, I.; Prüfer, D.; Dahm, M.; Meyer, J.; Oelert, H.; Darius, H. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J. Pharmacol. Exp. Ther. 1998, 286, 429–438.
13. Zhang, C.; Kimura, S.; Nishiyama, A.; Shokoji, T.; Rahman, M.; Yao, L. Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc. Res. 2005, 65, 230–238. [CrossRef] [PubMed]
14. Singh, P.N.; Athar, M.S. Simplified calculation of mean QRS vector (mean electrical axis of heart) of electrocardiogram. Indian J. Physiol. Pharmacol. 2003, 47, 212–216.
15. Karthikeyan, K.; SaralaBai, B.R.; Devaraj, S.N. Cardioprotective effect of grape seed proanthocyanidins on isoproterenol-induced myocardial injury in rats. Int. J. Cardiol. 2007, 115, 326–333. [CrossRef]
16. Asdaq, S.M.B.; Inamdar, M.N. Pharmacodynamic interaction of captopril with garlic in isoproterenol-induced myocardial damage in rat. *Phytother. Res.* 2010, 24, 720–725. [CrossRef] [PubMed]
17. Alnaqeeb, M.A.; Thomson, M.; Bordiab, T.; Ali, M. Histopathological effects of garlic on liver and lung of rats. *Toxicol. Lett.* 1996, 85, 157–164. [CrossRef]
18. Senthilkumar, S.H.; Anandan, R.; Devaki, T.; Santhosh Kumar, M. Cardioprotective effect of *Picrorrhiza kurroa* against isoproterenol-induced myocardial stress in rats. *Fitoterapia* 2001, 72, 402–405. [CrossRef]
19. Vasiljevic, Z.; Boskovic, A.; Ostoje, M.; Prostran, M.; Kocev, N. Long-term effect of captopril on plasma lipids in acute myocardial infarction: Possible mechanism. *Med. Biol.* 1999, 6, 69–72.
20. Fontes, J.P.; Gonçalves, M.; Ribeiro, V.G. Serum markers for ischemic myocardial damage. *Rev. Port. Cardiol.* 1999, 18, 1129–1136.
21. Kesavarao, K.E.; Venkatchalam, S.; Thiruvengadam, D. Effect of arginine and lysine on mitochondrial function during isoproterenol induced myocardial infarction in rats. *Nutr. Res.* 2003, 23, 1417–1425.
22. Ithayarasi, A.P.; Devi, C.S.S. Effect of alpha tocopherol on lipid peroxidation in isoproterenol induced myocardial infarction in rats. *Indian J. Phys. Pharmacol.* 1997, 41, 369–376.
23. Ru, Z.; Qingbin, X.; Ping, Z.; Lin, Y.; Jie, Z.; Guidong, D. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. *Eur. J. Pharmacol.* 2008, 586, 244–250.
24. Balaswamy, K.; Rao, P.G.P.; Rao, G.N.; Satyanarayana, A. Physico-chemical and antioxidant properties of foam mat dried muskmelon (*Cucumis melo*) and application in dairy products. *J. Sci. Ind. Res.* 2016, 75, 225–230.
25. McCord, J.M. Free radicals and myocardial ischemia. *Free Radic. Biol. Med.* 1988, 4, 9–13. [CrossRef]
26. Guarnieri, C.; Flamigni, F.; Calderera, C.M. Role of oxygen in cellular damage induced by reoxygenation of hypoxic heart. *J. Mol. Cell Cardiol.* 1980, 12, 797–808. [CrossRef]
27. Ismail, H.I.; Chan, K.W.; Mariad, A.A.; Ismail, M. Phenolic content and antioxidant activity of cantaloupe (*Cucumis melo*) methanolic extracts. *Food Chem.* 2010, 119, 643–647. [CrossRef]
28. Dai, J.; Mumper, R.J. Plant phenolics: Extraction, analysis and their antioxidant and anticancer properties. *Molecules* 2010, 15, 7313–7352. [CrossRef] [PubMed]